After a court ruled in favor of Teva in its Treanda patent case, Wells Fargo believes that the patent for Teva's Treanda drug will be preserved for a year or longer than it had expected. Wells says that it and the Street may have underestimated Treanda sales for this year. Wells notes that Treanda generates about $740M in annual sales for Teva. The firm keeps an Outperform rating on the shares.

Vanda Pharmaceuticals "announced that the Supreme Court denied Vanda's petition for a writ of certiorari in its HETLIOZ(R) Abbreviated New Drug Application litigation against Teva Pharmaceuticals USA, Inc., Apotex Inc. and Apotex Corp." CEO Mihael H. Polymeropoulos stated: "We are disappointed that the Supreme Court has decided not to hear our case and clarify the lower court standard for obviousness in patent law. However, we are pleased that our case has drawn attention to an area of law that has broad and significant implications in life sciences innovation."